ReviewGene therapy2012
Prospects for gene transfer for clinical heart failure.
Review in Gene therapy, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 23 citations in OpenAlex.
- Nanotechnology-enabled gene delivery for cancer and other genetic diseases.Expert opinion on drug delivery · 2023Review
- Effective Delivery of Hypertrophic miRNA Inhibitor by Cholesterol-Containing Nanocarriers for Preventing Pressure Overload Induced Cardiac Hypertrophy.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2019Article
- Raf kinase inhibitor protein: lessons of a better way for β-adrenergic receptor activation in the heart.The Journal of physiology · 2017Review
- Gene Therapy in Cardiac Surgery: Clinical Trials, Challenges, and Perspectives.The Annals of thoracic surgery · 2016Review
- Type VI adenylyl cyclase negatively regulates GluN2B-mediated LTD and spatial reversal learning.Scientific reports · 2016Article
- A needleless liquid jet injection delivery method for cardiac gene therapy: a comparative evaluation versus standard routes of delivery reveals enhanced therapeutic retention and cardiac specific gene expression.Journal of cardiovascular translational research · 2014Article
- Cardiovascular gene therapy for myocardial infarction.Expert opinion on biological therapy · 2014Review
- Therapeutic safety of high myocardial expression levels of the molecular inotrope S100A1 in a preclinical heart failure model.Gene therapy · 2014Article
- An emerging adeno-associated viral vector pipeline for cardiac gene therapy.Human gene therapy · 2013Review
- Heart failure gene therapy: the path to clinical practice.Circulation research · 2013Review
- Adenylyl cyclase subtype-specific compartmentalization: differential regulation of L-type Ca2+ current in ventricular myocytes.Circulation research · 2013Article
- Myocardial gene transfer: routes and devices for regulation of transgene expression by modulation of cellular permeability.Human gene therapy · 2013Review
- AAV-mediated gene therapy for heart failure: enhancing contractility and calcium handling.F1000prime reports · 2013Article
- Gene and cell therapies for the failing heart to prevent sudden arrhythmic death.Minerva cardioangiologica · 2012Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
Abstract
Congestive heart failure is an inexorable disease associated with unacceptably high morbidity and mortality. Preclinical results indicate that gene transfer using various proteins is a safe and effective approach for increasing function of the failing heart. In the current review, we provide a summary of cardiac gene transfer in general and summarize findings using adenylyl cyclase 6 as therapeutic gene in the failing heart. We also discuss the potential usefulness of a new treatment for congestive heart failure, paracrine-based gene transfer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.